Indraprastha Medical Corporation
Indraprastha Medical Corporation (INDRAMEDCO) share price was ₹313.60 at the 28 Oct 2026 close; market capitalisation ₹2,875 Cr; P/E (TTM) 15.29; sector Healthcare Services. The share price fell 44.4% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 11.2% year on year to ₹406.1 Cr and net profit rose 8.4% year on year to ₹55.8 Cr (compared with Jun 2025). Promoters held 51.00% of Indraprastha Medical Corporation in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 59/100 (Good) as of 28 Oct 2026.
Key Fundamentals
MicrocapHealthcare ServicesHealthcarePrice-based figures as of 28 Oct 2026, 15:31 IST · EPS basis: Standalone · TTM
Peer Comparison
Healthcare › Healthcare Services › Hospitals › Hospital
| ₹8,137.00 | 55.99 | 1,16,998 Cr | 12.34 | 0.26% | 20.08% | 19.79% | 26,675 Cr | 2,171 Cr | |
| ₹643.25 | 85.77 | 84,612 Cr | 5.15 | 0.00% | 10.42% | 9.50% | 11,400 Cr | 906 Cr | |
| ₹851.50 | 56.84 | 82,877 Cr | 7.71 | 0.24% | 13.42% | 12.70% | 8,879 Cr | 1,457 Cr | |
| ₹669.45 | 108.85 | 58,354 Cr | 13.87 | 0.45% | 8.84% | 9.71% | 5,006 Cr | 363 Cr | |
| ₹759.50 | 54.72 | 57,339 Cr | 5.79 | 0.14% | 10.47% | 12.13% | 9,607 Cr | 1,070 Cr | |
| ₹1,723.10 | 43.14 | 35,213 Cr | 7.76 | 0.26% | 17.85% | 11.39% | 9,185 Cr | 816 Cr | |
| ₹1,283.00 | 62.01 | 34,496 Cr | 8.71 | 0.04% | 13.91% | 15.05% | 4,800 Cr | 552 Cr | |
| ₹313.60 | 15.29 | 2,875 Cr | 3.88 | 1.28% | 24.80% | 30.67% | 1,554 Cr | 188 Cr | |
| Median 8 companies | ₹805.50 | 56.42 | 57,847 Cr | 7.73 | 0.25% | 13.67% | 12.42% | 9,032 Cr | 861 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100. How it works →
v2.0.0
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
4- Company is almost debt free.
- Company has delivered good profit growth of 132% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 28.7%
- Company has been maintaining a healthy dividend payout of 26.3%
Technical Indicators
Oscillators
Bearish
Overall
Bearish
Moving Averages
Bearish
1 of 1 analyst rates Buy, 0 Hold, 0 Sell.
Updated 28 Oct 2026
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 20% · Jun 2026
AI Analysis — Bull vs Bear
Indraprastha Medical Corporation Ltd operates the 710-bed Indraprastha Apollo Hospital in Delhi and trades at a P/E of 19.4x with a market cap of Rs 3,518 Cr. The company has delivered 132% profit CAGR over 5 years and maintains a 3-year ROE of ~29%, but the stock has declined ~23-25% over the past year despite continued revenue and profit growth.
- Virtually debt-free balance sheet provides financial resilience and flexibility for expansion without interest burden
- Exceptional 5-year profit CAGR of 132% demonstrates strong operating leverage as revenue scaled from Rs 888 Cr (FY22) to Rs 1,483 Cr (FY26)
- Consistent ROE of 27-29% over 3-5 years indicates efficient capital deployment well above cost of equity
- Operating profit margins have expanded from 12.8% in FY22 to 17.7% in FY26, showing sustained margin improvement
- Revenue grew 9% TTM and 11% CAGR over 3 years, indicating steady top-line momentum in a single-hospital model
- Healthy dividend payout ratio of 26.3% with 1.16% yield signals cash generation discipline and shareholder return focus
- 710-bed flagship hospital in prime Delhi location benefits from medical tourism flows and high-acuity case mix
- EPS has grown from Rs 6.39 (FY20) to Rs 20.03 (FY24), a 3x increase in four years
- Stock has declined ~23-25% over the past year, significantly underperforming the broader market and healthcare peers
- Single-asset concentration risk — entire business depends on one 710-bed hospital in Delhi with no geographic diversification
- TTM revenue growth has decelerated to 9% from 24% (FY23) and 45% (FY22), suggesting growth normalization post-COVID tailwinds
- P/B ratio of 4.81x is elevated for a company with limited physical expansion runway in its current structure
- Small-cap at Rs 3,518 Cr market cap with limited institutional coverage and lower liquidity compared to larger hospital chains
- Government lease obligation requires one-third of 600 beds for free treatment, creating a structural margin ceiling
- 10-year revenue CAGR of only 7% highlights that long-term top-line growth has been modest outside the post-COVID recovery period
- Capacity constrained at 710 beds with limited scope for bed additions at the existing Delhi campus, capping organic growth
This is AI-generated analysis, not financial advice. Do your own due diligence.
Analyst Forecasts
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 307 | 317 | 306 | 315 | 348 | 350 | 325 | 334 | 365 | 381 | 372 | 365 | 406 |
| Expenses | 259 | 267 | 259 | 266 | 281 | 286 | 273 | 272 | 292 | 310 | 310 | 304 | 326 |
| Operating Profit | 47 | 50 | 47 | 48 | 67 | 64 | 52 | 61 | 73 | 71 | 62 | 61 | 80 |
| OPM % | 15% | 16% | 15% | 15% | 19% | 18% | 16% | 18% | 20% | 19% | 17% | 17% | 20% |
| Other Income | 4 | 4 | 4 | 5 | 5 | 6 | 5 | 6 | 7 | 7 | 7 | 7 | 8 |
| Interest | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 1 | 1 | 2 |
| Depreciation | 10 | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 10 | 11 | 11 | 11 | 12 |
| PBT | 40 | 44 | 41 | 42 | 60 | 57 | 45 | 55 | 68 | 66 | 56 | 55 | 75 |
| Tax % | 24% | 25% | 28% | 25% | 25% | 26% | 26% | 26% | 25% | 25% | 27% | 24% | 25% |
| Net Profit | 30 | 33 | 29 | 31 | 45 | 42 | 33 | 41 | 51 | 49 | 41 | 42 | 56 |
| EPS (₹) | 3.33 | 3.58 | 3.21 | 3.4 | 4.88 | 4.63 | 3.58 | 4.47 | 5.61 | 5.4 | 4.47 | 4.55 | 6.09 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 714 | 755 | 766 | 753 | 788 | 831 | 613 | 888 | 1,099 | 1,245 | 1,356 | 1,483 | 1,524 |
| Expenses | 630 | 675 | 686 | 678 | 706 | 743 | 572 | 768 | 947 | 1,050 | 1,112 | 1,215 | 1,250 |
| Operating Profit | 85 | 80 | 79 | 74 | 82 | 87 | 41 | 120 | 152 | 195 | 245 | 267 | 274 |
| OPM % | 12% | 11% | 10% | 10% | 10% | 11% | 7% | 14% | 14% | 16% | 18% | 18% | 18% |
| Other Income | 1 | 1 | 0 | -1 | -1 | 0 | 0 | -3 | 9 | 16 | 22 | 28 | 30 |
| Interest | 8 | 7 | 8 | 9 | 7 | 6 | 3 | 3 | 4 | 4 | 6 | 6 | 6 |
| Depreciation | 28 | 35 | 31 | 31 | 30 | 33 | 33 | 35 | 39 | 40 | 44 | 44 | 45 |
| PBT | 50 | 39 | 41 | 34 | 45 | 48 | 4 | 79 | 117 | 166 | 216 | 246 | 253 |
| Tax % | 34% | 37% | 36% | 38% | 36% | 9% | 46% | 26% | 26% | 25% | 26% | 25% | — |
| Net Profit | 32 | 24 | 26 | 21 | 28 | 44 | 2 | 59 | 86 | 124 | 161 | 184 | 188 |
| EPS (₹) | 3.54 | 2.66 | 2.86 | 2.3 | 3.1 | 4.76 | 0.25 | 6.39 | 9.4 | 13.52 | 17.56 | 20.03 | 20.51 |
| Div. Payout % | 51% | 68% | 63% | 65% | 52% | 0% | 0% | 39% | 32% | 33% | 26% | 20% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 |
| Reserves | 103 | 132 | 139 | 141 | 152 | 176 | 181 | 234 | 288 | 386 | 505 | 649 |
| Borrowings | 50 | 52 | 67 | 66 | 21 | 4 | 3 | 5 | 2 | 34 | 33 | 37 |
| Other Liabilities | 196 | 185 | 160 | 134 | 157 | 177 | 157 | 131 | 173 | 212 | 222 | 214 |
| Total Liabilities | 442 | 460 | 458 | 432 | 422 | 449 | 432 | 462 | 555 | 723 | 852 | 991 |
| Fixed Assets | 286 | 301 | 296 | 294 | 280 | 303 | 283 | 277 | 275 | 347 | 328 | 365 |
| CWIP | 3 | 3 | 0 | 0 | 1 | 0 | 3 | 0 | 3 | 0 | 33 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 153 | 157 | 163 | 138 | 141 | 146 | 145 | 185 | 278 | 376 | 491 | 624 |
| Total Assets | 442 | 460 | 458 | 432 | 422 | 449 | 432 | 462 | 555 | 723 | 852 | 991 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 64 | 62 | 28 | 48 | 75 | 86 | 27 | 94 | 144 | 200 | 157 | 167 |
| Investing | -29 | -33 | -22 | -30 | -17 | -40 | -19 | -74 | -108 | -158 | -111 | -178 |
| Financing | -35 | -30 | -5 | -17 | -44 | -43 | -3 | -3 | -26 | -32 | -46 | -46 |
| Net Cash Flow | 0 | 0 | 0 | 1 | 14 | 4 | 5 | 17 | 11 | 9 | 0 | -57 |
| Free Cash Flow | 35 | 29 | 5 | 17 | 58 | 46 | 6 | 65 | 100 | 131 | 120 | 108 |
| CFO/EBITDA | 98 | 104 | 57 | 82 | 110 | 113 | 88 | 95 | 102 | 127 | 89 | 88 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 40 | 41 | 47 | 41 | 35 | 35 | 40 | 18 | 23 | 17 | 20 | 28 |
| Cash Conversion Cycle | 40 | 41 | 47 | 41 | 35 | 35 | 40 | 18 | 23 | 17 | 20 | 28 |
| Working Capital Days | -35 | -22 | -17 | -7 | -5 | -10 | -1 | -2 | -12 | -24 | -19 | -4 |
| ROCE % | 23% | 18% | 17% | 15% | 19% | 21% | 3% | 29% | 34% | 38% | 39% | 36% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Indraprastha Medical Corporation insights
60 extracted metrics + investor summaries across FY10–FY27.
Documents
Frequently Asked Questions about Indraprastha Medical Corporation
What does Indraprastha Medical Corporation Ltd do?
Where is Indraprastha Medical Corporation Ltd (INDRAMEDCO) listed?
Which sector does Indraprastha Medical Corporation Ltd belong to?
What is the market capitalisation of Indraprastha Medical Corporation Ltd?
What is the PE ratio of Indraprastha Medical Corporation Ltd?
What is the 52-week high and low of Indraprastha Medical Corporation Ltd?
Does Indraprastha Medical Corporation Ltd pay dividends?
What is the Return on Equity (ROE) of Indraprastha Medical Corporation Ltd?
Company Information
Incorporated in 1988 as a JV between Apollo Hospitals Enterprise Ltd. (AHEL) and the Delhi Government, Indraprastha Medical Corporation Ltd. is a super speciality tertiary care hospital in New Delhi. The Co. currently has 52 speciality departments. [1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/INDRAMEDCO.md for Indraprastha Medical Corporation Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.